Client Portal - Agenda

Log On

Tuesday, September 27, 2022

MACQUARIE CHINA COSMETIC ACCESS DAY

Macquarie invites you to join our China Cosmetic Access Day on Tuesday, 27 September 2022.

We have invited Imeik (300896 CH) to discuss the company's 2H22 outlook and new product development progress. Our industry experts will discuss their views on the China medical aesthetics industry's regulatory outlook, consumer behaviour changes since Covid, and the potential of new markets such as Botox and Collagen.

Our conference calls will help you understand the latest trends in the medical aesthetics space and explore key emerging industry themes driving the future growth of the China beauty sector. We see secular growth opportunities in China's medical aesthetics space driven by rising incomes, changing demographics, and increasing self-care, while increasing regulations should favour established players.

AGENDA (Tuesday, 27 September 2022 [Mandarin only])
09:00-09:50am HKT: Imeik (300896 CH) *Limited Capacity* - Patrick LI, IR director
10:00-10:50am HKT: Expert Session: China medical aesthetics industry (hyaluronic acid dermal fillers, botox, regenerative dermal fillers) sales update and competitive landscape - The expert is in charge of the overall planning of a medical aesthetics marketing platform for 6 years. Expert is knowledgeable in the latest sales trends and competitive landscape forhyaluronic acid dermal fillers, botox, regenerative dermal fillers markets.)
11:00-11:50am HKT: Expert Session: China collagen industry outlook - The expert has more than 15 years of experience in the injectable collagen field. He previously served as the head of R&D at a leading Medicine and Biological Technology company in Changchun and successfully spearheaded the development of China's first collagen injection product, "Fillderm". He is currently the general manager of a Bioengineering Technology company.

This information is a general description of the Macquarie Group only. Before acting on any information, you should consider the appropriateness of it having regard to your particular objectives, financial situation and needs and seek advice. No information set out above constitutes advice, an advertisement, an invitation, an offer or a solicitation, to buy or sell any financial product or security or to engage in any investment activity, or an offer of any banking or financial service. Some products and/or services mentioned on this website may not be suitable for you and may not be available in all jurisdictions.

Macquarie only carries on banking activities in those countries it is authorised to do so. Macquarie Bank Limited (MBL) is authorised by the Australian Prudential Regulation Authority (APRA) in Australia to carry out banking business in Australia. Each of MBL, acting through its London branch, and Macquarie Bank International Limited, is authorised and regulated by the UK Financial Conduct Authority to carry on banking business in the United Kingdom. MBL, acting through its Seoul Branch, is authorised and regulated by the Financial Services Commission in Korea to carry out banking business in Korea. MBL, acting through its Singapore Branch, is authorised and regulated by the Monetary Authority of Singapore to carry out banking business in Singapore. MBL, acting through its branch in the Dubai International Finance Centre, is authorised and regulated by the Dubai Financial Services Authority to carry out banking business in Dubai.

Other than MBL, any Macquarie Group entity noted on this page is not an authorized deposit-taking institution for the purposes of the Banking Act 1959 (Commonwealth of Australia). That entity's obligations do not represent deposits or other liabilities of MBL. MBL does not guarantee or otherwise provide assurance in respect of the obligations of that entity, unless noted otherwise.

Macquarie Group Limited and its related corporations are not otherwise currently authorized to accept deposits or conduct banking business in any other jurisdiction. Other members of the Macquarie Group are subject to regulation in the regions in which they operate. Further information can be found on this website or by contacting us.